Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on July 5, 2024.

Summary

• Lilly Endowment Inc. sold 50,540 shares of Eli Lilly & Co. common stock at a weighted average price of $915.144 per share on July 5, 2024.
• Additionally, Lilly Endowment Inc. sold 1,829 shares of Eli Lilly & Co. common stock at a weighted average price of $916.247 per share on the same day.
• Following these transactions, Lilly Endowment Inc. beneficially owns 97,247,403 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment. It is a routine filing.

Industry Context

This filing is a routine disclosure of stock transactions by a major shareholder and is typical for companies with significant institutional ownership. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies.
• The transaction is similar to other large institutional investors adjusting their positions in response to market conditions or portfolio rebalancing.
• The sale of shares by Lilly Endowment Inc. is not unusual given their large holdings in Eli Lilly & Co.

Stakeholder Impact

• The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, SEC Form 4